FluoroPharma Medical (FPMI) 10-Q2013 Q3 Quarterly report

Filed: 14 Nov 13, 12:00am

Content analysis

Positive
Negative
Uncertain
Constraining
Legalese
Litigious
Readability	H.S. sophomore Bad

New words: affirmative, alter, alteration, anniversary, arriving, binomial, classification, classified, compounded, comprised, consent, counsel, counted, create, criteria, dollar, earliest, embedded, exposure, external, face, final, freely, fundamental, involuntarily, iv, JAD, light, manner, mutual, October, pertaining, premium, program, provision, publicly, rank, ranking, reclassification, reduction, render, repeal, resale, residual, revaluation, senior, separate, separately, single, slowly, suspended, table, tradable, unrealized, voluntarily, waive

Removed: ability, accredited, agreeing, angina, arterial, atherosclerotic, Bloomberg, cap, cerebral, chest, clot, contract, core, correlate, critical, decrease, desirable, differentiated, execute, factor, formation, FPM, grow, independent, infiltration, inflammation, inflammatory, ischemia, key, large, lumen, narrow, narrowing, NJ, objective, opportunity, overlying, pain, presence, progressively, published, reliance, represented, rest, rupture, size, thin, thought, thrombi, unaddressed, unmet

Search this filing

Filing tables

Export all tables to Excel

Filing exhibits

FPMI similar filings

Filing view

Default size S M L
Default font Times Arial

External links

Share this filing

Exhibit 32.1

CERTIFICATION PURSUANT TO

18 U.S.C. SECTION 1350,

AS ADOPTED PURSUANT TO

SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

In connection with the Quarterly Report of FluoroPharma Medical, Inc. a Nevada corporation (the “Company”), on Form 10-Q for the quarterly period ending September 30, 2013 as filed with the Securities and Exchange Commission (the “Report”), I, Johan Spoor, Chief Executive Officer of the Company, certify, pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, 18 U.S.C. Section 1350), that to my knowledge:

(1) The Report fully complies with the requirements of section 13(a) or 15(d) of the Securities Exchange Act of 1934 (15 U.S.C. 78m or 78o(d)); and

(2) The information contained in the Report fairly presents, in all material respects, the financial condition and result of operations of the Company.

/s/ Johan M. (Thijs) Spoor
Johan M. (Thijs) Spoor
President and Chief Executive Officer (Principal Executive Officer)
Date: November 14, 2013